Japan, China stocks lead Asia gains on yen, data
HONG KONG (AP) — Japanese and Chinese shares led Asian markets higher Wednesday as the Nikkei touched a fresh high on the yen's slump and Chinese business surveys offered some optimism about the world's No. 2 economy.
KEEPING SCORE: Japan's benchmark Nikkei 225 index added 1 percent to 17,845.91, after rising as high as 17,881.76 earlier, the highest level since mid-2007. South Korea's Kospi edged up 0.2 percent to 1,969.27 and Hong Kong's Hang Seng rose 0.6 percent to 23,799.30 while the Shanghai Composite Index in mainland China gained 0.9 percent to 2,789.96. Australia's S&P/ASX 200 rose 0.4 percent to 5,302.20.
YEN SLUMP: The Nikkei's rise comes as the Japanese currency falls to its lowest in seven years, with the latest catalyst coming in the form of a downgrade by ratings service Moody's to the government's credit rating. The dollar strengthened to 119.33 yen from 119.22 yen in late trading Tuesday. The weakening yen, driven by the government's monetary easing aimed at stimulating the economy, is good for the nation's big exporters such as Toyota and Canon because it makes their cars and electronics cheaper overseas.
CHINA SERVICES: Shanghai shares jumped after two monthly surveys showed that activity in the No. 2 economy's service industries edged higher. The results of an official purchasing managers' index and a similar one by HSBC, which showed that new orders rose at their fastest in two and half years, were encouraging signs after a recent string of downbeat data.
WALL STREET: The Dow Jones industrial average gained 0.6 percent to a record close of 17,879.55. The Standard & Poor's 500 rose 0.6 percent to close at 2,066.55. The Dow Jones industrial average gained 0.6 percent to 17,879.55, while the Nasdaq composite rose 0.6 percent to 4,755.81.
ENERGY: Oil prices rebounded, with benchmark U.S. crude rising 79 cents to $67.67 a barrel in electronic trading on the New York Mercantile Exchange. The contract fell $2.12 to settle at $66.88 a barrel on Tuesday. Brent crude, used to price internationally, rose 62 cents to $71.16 on the ICE Exchange in London.
Japan, China stocks lead Asia gains on yen, data : Business
Japan’s Otsuka to Buy Avanir Pharmaceuticals
With $3.5 Billion U.S. Deal, Abilify Maker Is Latest Japanese Drug Firm to Push Abroad
TOKYO—Otsuka Pharmaceutical Co. agreed to buy
Avanir Pharmaceuticals Inc. of the U.S. for $3.5 billion, the latest large deal by a Japanese drug maker looking to expand overseas.
The deal gives Otsuka, maker of the schizophrenia and depression drug Abilify, access to more treatments for central-nervous-system diseases. California-based Avanir sells Nuedexta, a treatment for a condition known as pseudobulbar affect that causes sudden and involuntary outbursts in patients with neurological diseases such as amyotrophic lateral sclerosis.
Otsuka Pharmaceutical, part of
Otsuka Holdings Co. , said it would pay $17 a share in cash for Nasdaq-traded Avanir. The deal is the largest purchase by Otsuka Holdings, which listed its shares in an initial public offering in Tokyo in 2010, giving it more resources for acquisitions. Like other Japanese pharmaceutical companies, Otsuka has been looking abroad as growth slows in the domestic market, the second-largest after the U.S.
Otsuka Holdings President Tatsuo Higuchi said at a news conference that Avanir’s strengths in neurological diseases would complement Otsuka’s experience in the area of mental illnesses. “We’ll try to maximize the integration effect,” he said.
Avanir Chief Executive Keith Katkin said in a written statement, “Together, our organizations will be able to more rapidly develop and commercialize needed medications.” Avanir, which was founded in 1988 as Lidak Pharmaceuticals, is conducting trials of medicines for depression, migraine headaches and other neurological diseases.
Some pharmaceutical companies have been reducing their involvement in those areas because of the large number of generic drugs available and the long period required for clinical trials and regulatory approval. But Otsuka is trying to build on its existing business and find new products to make up for Abilify, whose patent is set to expire in 2015 according to the company.
Otsuka has been bulking up in recent years and bought U.S. cancer-drug maker Astex Pharmaceuticals Inc. last year for about $886 million.
“From our experience, we value creativity which can be generated from cultural diversity and different ways of thinking,” Mr. Higuchi said. “I learned it from the late Chairman Otsuka,” he added, a reference to longtime executive Akihiko Otsuka, who died last Friday at the age of 77. Mr. Otsuka, a member of the founding family, was involved in the development of the company’s food and beverage arm, helping to create the Pocari Sweat sports drink and Calorie Mate energy bar.
Mr. Higuchi said the yen’s recent fall didn’t affect Otsuka’s decision-making on overseas acquisitions. “We’ll make a move when it should be done,” Mr. Higuchi said, adding that Otsuka would use funds it holds in dollars for part of the purchase.
The acquisition of Avanir is the latest among sizable overseas deals by Japanese pharmaceutical companies, which have included
Takeda Pharmaceutical Co. ’s purchases of Millennium Pharmaceuticals and Nycomed,
Astellas Pharma Inc. ’s acquisition of OSI Pharmaceuticals and
Daiichi Sankyo Co. ’s deal for a controlling stake in
Ranbaxy Laboratories Ltd.
The deals have given the Japanese companies broader access to overseas markets, but some have run into trouble. Daiichi sold its Ranbaxy stake this year, six years after the acquisition, following a series of regulatory problems. Takeda has faced questions from shareholders over its integration of Nycomed and Millennium. The company recently brought in a French executive as president and has said it would seek to break down internal silos.
http://online.wsj.com/articles/japans-otsuka-to-buy-drug-maker-avanir-in-3-5-billion-deal-1417513161
Japan’s nuclear restart to boost Australian uranium industry
The Minerals Council of Australia says Australia’s uranium industry is set for a boost as Japan moves to restart nuclear reactors for the first time since the Fukushima meltdown.
Two reactors at Japan’s Sendai nuclear plant in the south west of the country are due to restart next year after receiving approval from local governor Yuichiro Ito.
This is the first time a reactor will restart since an earthquake triggered a tsunami in 2011, causing a meltdown at the Fukushima facility.
All of Japan’s 48 nuclear plants were shut down in response, but Prime Minister Shinzo Abe has been pushing for their reopening as the cost of importing oil and gas hurts the Japanese economy,
BBC reported.
Before the meltdown nuclear energy produced around 30 per cent of Japan’s power.
"I have decided that it is unavoidable to restart the No. 1 and No. 2 Sendai nuclear reactors," Ito said.
"I have said that assuring safety is a prerequisite and that the government must ensure safety and publicly explain it thoroughly to residents."
Executive director for uranium at the Minerals Council of Australia Daniel Zavattiero said the move was good news for the local uranium industry and its 4000 workers.
“Japan has been a major export destination for Australian uranium and its re-entry to the market will boost investment and development of the Australian industry,” Zavattiero said.
“Japan’s decision also sends a strong signal affirming nuclear’s role in meeting the world’s growing demand for energy.”
The price of uranium collapsed after the 2011 disaster and had been hovering at around $36.75 a pound, forcing many miners to shut their operations.
The announcement of the nuclear restart prompted a 14 per cent rise in price to $42 a pound last week.
However analysts say a price of around $60 a pound is required for uranium producers to reopen their mines.
Japan’s nuclear restart to boost Australian uranium industry | Mining Australia
Japan's Nikkei marks sixth day of gains
Japanese shares saw their sixth consecutive day of gains on Friday, marking their longest winning streak since August.
The benchmark Nikkei 225 closed up 0.2% to 17,920.45 points, which was its best finish since July 2007.
The dollar also rose past the 120-yen mark for the first time in seven-and-a-half years.
The rest of Asia traded mixed after the European Central Bank (ECB) decided not to expand its stimulus programme.
In a meeting on Thursday, the ECB put off a possible full quantitative
easing programmeuntil early next year.
Investors also kept a close an eye on US jobs data due later in the day for signs of growth in the world's largest economy.
In China, Hong Kong's Hang Seng index rose 0.9% to 24,035.98, adding to the previous session's big gains, while the Shanghai Composite was down 0.3% at 2,891.4.
In Australia, the benchmark S&P/ASX 200 closed down 0.6% at 5,335.3, dragged lower by mining and energy firms.
Shares of mining services firm Bradken jumped more than 36% after receiving a 872m Australian dollar ($731m; £467m) takeover approach from buyout firms Pacific Equity Partners and Bain Capital.
South Korean shares ended flat after the country's trade ministry saying that exports were likely to grow 2.8% in 2014 to a record $575bn (£367bn).
The ministry forecast that South Korea would post a trade surplus of about $45bn this year, also the largest on record.
The benchmark Kospi index finished at 1,986.62.
BBC News - Japan's Nikkei marks sixth day of gains